LillyDirect vs. NovoCare vs. Compounded: The Direct-to-Consumer Verdict
Novo Nordisk and Eli Lilly both sell directly to patients now, bypassing traditional pharmacy channels. Add compounded into the mix and you have three distinct paths to GLP-1 medication. Here's when each makes sense.
The Verdict
NovoCare wins for pen-based injection and cardiovascular benefit â $349/mo Wegovy across all doses. LillyDirect wins for the lowest branded price â $299/mo for 2.5mg Zepbound vials, up to $449 for higher doses. Compounded wins on absolute lowest price â $146â249/mo through telehealth. Choose based on budget, format preference, and how much you value FDA oversight.
For years, patients had one path to brand-name GLP-1 medication: doctor writes prescription â pharmacy fills it â insurance pays or you pay full retail (usually $950â1,200). That model broke in late 2025 when both Novo Nordisk and Eli Lilly launched direct-to-consumer pharmacy channels at dramatically lower prices.
Combined with the compounded market, patients now have three distinct purchase paths. Understanding where each fits is the difference between overpaying and getting exactly what you need.
The three pathways
| Feature | NovoCare Pharmacy | LillyDirect | Compounded (Telehealth) |
|---|---|---|---|
| Medication | Wegovy, Ozempic | Zepbound (vials) | Semaglutide, tirzepatide |
| Format | Pen injector | Vials (some pens) | Vials, oral, lozenges, drops |
| Price range | $349/mo Wegovy | $299â$449/mo | $146â$249/mo |
| Subscription option? | Via telehealth partners | No | Month-to-month |
| FDA approval? | Yes | Yes | No (503A compounded) |
| Prescription required? | Yes (your PCP or Novo's partner telehealth) | Yes (your PCP or Lilly's partner) | Yes (via telehealth platform) |
| Insurance? | Cash-pay primary | Cash-pay primary | Cash-pay only |
NovoCare Pharmacy: the manufacturer direct model
NovoCare Pharmacy launched in 2024 and expanded significantly through 2025. It sells Wegovy and Ozempic directly to self-pay patients at $349/month flat across all doses. Patients still need a prescription from a licensed provider (your PCP, endocrinologist, or a telehealth platform partnered with Novo).
- Price: $349/month Wegovy, all doses (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg).
- Format: Wegovy pen injector â familiar, simple, requires no measuring.
- Shipping: Direct to patient, refrigerated shipping.
- What NovoCare won't do: It doesn't offer the subscription pricing ($249/mo 12-month plans) â those are only available through Novo's telehealth partners (Ro, WW, LifeMD, Hims, Sesame).
LillyDirect: the vial-pricing play
LillyDirect launched in January 2024 and expanded Zepbound vial access dramatically in December 2025. The company's pricing strategy targets compounded competitors specifically â by offering vials at $299/mo (2.5mg dose) and up to $449/mo (higher doses), Lilly positioned itself as "FDA-approved at compounded prices."
- 2.5mg vial: $299/month (starter dose)
- 5mg vial: $399/month
- 7.5mgâ15mg vials: $449/month each
- Key constraint: 45-day refill rule â you must wait 45 days between orders. Designed to prevent stockpiling.
- Vial vs. pen: Vials require you to draw the medication into a syringe. Slightly more involved than pen injection, but the price is lower.
Compounded telehealth: the lowest-price alternative
Compounded semaglutide and tirzepatide through telehealth platforms (Yucca, MEDVi, Synergy, SHED, Sprout, Care Bare) offer prices from $146 to $249/month. The trade-off: no FDA approval of the finished product, compounded by state-licensed 503A pharmacies, consultation included.
The total annual cost comparison
| Path | Monthly | Annual |
|---|---|---|
| NovoCare Wegovy | $349 | $4,188 |
| LillyDirect Zepbound 2.5mg | $299 | $3,588 |
| LillyDirect Zepbound mid-dose | $399 | $4,788 |
| Wegovy subscription (Novo via telehealth) | $249 | $2,988 |
| Compounded (mid-range) | $200 | $2,400 |
| Compounded (cheapest) | $146 | $1,752 |
Which path fits which patient
- Insurance-covered patients: Skip all three. Your copay through insurance will usually beat any of these direct-pay options. Check coverage first.
- Self-pay with $350+/month budget: NovoCare or Wegovy telehealth subscription for pen injection convenience.
- Self-pay wanting lowest branded price: LillyDirect Zepbound vials at $299 if you're willing to use vials.
- Self-pay with tight budget: Compounded at $146â249/mo, with full understanding of the regulatory trade-offs.
- Self-pay wanting CV risk reduction: Wegovy (NovoCare or subscription) for the FDA-approved CV indication.
Bottom line
Three legitimate paths to GLP-1 medication now exist at prices that would have been unimaginable two years ago. The "right" choice is specific to your priorities. Budget-conscious patients win with compounded or LillyDirect. Convenience-conscious patients win with NovoCare or telehealth subscriptions. CV-risk patients should specifically choose Wegovy. Make the decision based on your real priorities rather than whichever marketing reached you first.